Gregory Kalemkerian, MD, FACP
Until the approval of immunotherapy agents in small cell lung cancer (SCLC), the treatment landscape for this tumor type had remained virtually unaltered for the past 2 decades. Successive investigations failed to broaden the portfolio of therapies.1
Now, with several agents in development, SCLC, which constitutes up to 15% of lung cancers, is the focus of increased clinical investigation that may make further treatment inroads.
It represented an alternative to the harsh adverse events associated with cisplatin. Cisplatin/etoposide and carboplatin/etoposide were the first-line standards of care for patients with SCLC until March 2019, which is when the FDA approved atezolizumab in combination with carboplatin and etoposide as a frontline treatment for adult patients with extensive-stage SCLC.
Figure. History of SCLC Approvals2,3
... to read the full story